Clone-level validation list shows translational researchers which markers Teiko has tested on fixed blood across mass and spectral cytometry, and to what extent.
SALT LAKE CITY, UT — November 18, 2026 — Teiko expanded its list of validated antibody clones to 148, spanning 116 markers in blood preserved with TokuKit. It’s a 3-step preservation kit that stabilizes samples at the clinical site for up to 24 months with results that correlate with fresh blood at r > 0.99. The TokuKit validated clone list covers mass cytometry (127 clones, 110 markers) and spectral flow cytometry (51 clones, 37 markers), with 31 markers validated on both platforms, representing an 11X coverage in antibodies over alternate stabilization kits.
Drug developers increasingly fix samples at collection because approximately 20% of blood samples fall out of spec during shipping and handling. While fixation can affect whether an antibody binds its epitope, Teiko has tested which clones still bind after samples have been fixed with TokuKit. Teams piloting TokuKit or running it in-house can check their markers of interest against the list and know before they start which clones to use and how much panel optimization to expect.
For each marker, the list gives the clone tested on each platform and the extent to which Teiko has evaluated it using the following criteria:
For markers not represented on the list, Teiko’s custom validation typically follows 7 steps:
Check whether your markers are validated: the TokuKit validated clone list is available now at teiko-labs.com/tokukit.
For questions, contact info@teiko-labs.com.